Advertisement

Riesenzellarteriitis (Arteriitis temporalis oder cranialis)

  • Peter Berlit
Living reference work entry
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Die Arteriitis temporalis (AT) ist eine Form der Riesenzellarteriitis, welche schwerpunktmäßig die A. carotis externa und ihre Äste betrifft, bei älteren Menschen (über 50 Jahre) auftritt und typischerweise mit Allgemeinsymptomen einhergeht. Serologisch finden sich ausgeprägte Entzündungszeichen, von denen eine meist deutliche Beschleunigung der Blutkörperchensenkungsgeschwindigkeit (BSG > 100 mm/h) und eine Erhöhung des C-reaktiven Proteins (CRP) diagnostisch am relevantesten sind. Etwa die Hälfte aller Patienten mit einer AT zeigt die Symptomatik einer Polymyalgia rheumatica (PMR) mit Schmerzen im Bereich der proximalen Muskulatur und Gelenke sowie Morgensteifigkeit. AT und PMR sind Facetten eines Krankheitsspektrums mit fließenden Übergängen. Zu den gefürchteten Komplikationen der Erkrankung zählen die ein- oder beidseitige Erblindung, Hirninfarkte und ein Befall der Aorta und ihrer Äste.

Literatur

  1. Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE (1994) How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 120:987–992CrossRefPubMedGoogle Scholar
  2. Alba MA, Garcia-Martinez A, Prieto-Gonzalez S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, Espigol-Frigole G, Butjosa M, Hernandez-Rodriguez J, Cid MC (2014) Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 93(5):194–201CrossRefGoogle Scholar
  3. Berlit P (1992) Clinical and laboratory findings with giant-cell-arteritis. J Neurol Sci 111:1–12CrossRefPubMedGoogle Scholar
  4. Berlit P (1997) Giant cell arteritis. In: Lechtenberg R, Schutta HS (Hrsg) Practice guidelines for neurologic therapy. Dekker, New YorkGoogle Scholar
  5. Berlit P (2010) Diagnosis and treatment of cerebral vasculitis. Ther Adv Neurol Disord 3:29–42CrossRefPubMedPubMedCentralGoogle Scholar
  6. Berlit P (2015) Basiswissen Neurologie, 6. Aufl. Springer, Berlin/Heidelberg/New York/TokioGoogle Scholar
  7. Berlit P, Kraemer M (2014) Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls. Clin Exp Immunol 175:419–424CrossRefPubMedPubMedCentralGoogle Scholar
  8. Bley TA, Uhl M, Carew J, Markl M et al (2007) Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol 28:1722–1727CrossRefPubMedGoogle Scholar
  9. Carrie F, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B (1994) Rifampicin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Arch Intern Med 154:1521–1524CrossRefPubMedGoogle Scholar
  10. Caselli RJ, Daube JR, Hunder GG, Whisnant JP (1988) Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology 38:685–689CrossRefPubMedGoogle Scholar
  11. Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB (1988) Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimen (11 year survey of 210 patients). Ann Rheum Dis 47:733–739CrossRefPubMedPubMedCentralGoogle Scholar
  12. Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford) 55(1):66–70CrossRefGoogle Scholar
  13. Generau T, Herson S, Pette JC et al (1992) Temporal arteritis in young subjects. A trial of nosological classification apropos of 6 cases. Ann Med Interne (Paris) 143:303–308Google Scholar
  14. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J (2005) Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 84(5):269–276CrossRefGoogle Scholar
  15. Hoffman GS, Cid MC, Hellmann DB et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309–1318CrossRefPubMedGoogle Scholar
  16. Hoffman GS, Cid MC, Rendt-Zagar KE, Infliximab-GCA Study Group et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621–630CrossRefPubMedGoogle Scholar
  17. Hunder GG, Weyand CM (1997) Sonography in giant-cell arteritis. N Engl J Med 337:1385–1386CrossRefPubMedGoogle Scholar
  18. Huston KA, Hunder GG (1980) Giant cell (cranial) arteritis: a clinical review. Am Heart J 100:99–107CrossRefPubMedGoogle Scholar
  19. Imakita M, Yutani C, Ishibashi-Ueda H (1993) Giant cell arteritis involving the cerebral arteries. Arch Pathol Lab Med 117:729–733PubMedGoogle Scholar
  20. Karassa FB et al (2005) Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 142(5):359–369CrossRefPubMedGoogle Scholar
  21. Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, Matteson EL (2013) Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 72(12):1989–1994CrossRefPubMedGoogle Scholar
  22. Kraemer M, Metz A, Herold M, Venker C, Berlit P (2011) Reduction in jaw opening: a neglected symptom of giant cell arteritis. Rheumatol Int 31:1521–1523CrossRefPubMedGoogle Scholar
  23. Liozon F, Vidal E, Gaches F et al (1992) Death in Horton disease. Prognostic factors. Rev Med Interne 13:187–191CrossRefPubMedPubMedCentralGoogle Scholar
  24. Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP, Merkel PA (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789–2797CrossRefPubMedGoogle Scholar
  25. Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625–630CrossRefPubMedGoogle Scholar
  26. Piper J, Salmon J, Wailoo A, Wolfe K, Hutchings A (2016) The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 20(90):1–238CrossRefPubMedPubMedCentralGoogle Scholar
  27. Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG (2003) Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49:703–708CrossRefGoogle Scholar
  28. Salvarani C, Soriano A, Muratore F, Shoenfeld Y, Blockmans D (2017) Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? Autoimmun Rev 16(11):1125–1130CrossRefPubMedGoogle Scholar
  29. Schmidt WA (2018) Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology 2018Google Scholar
  30. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer D, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N (2017) Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 377(4):317–328CrossRefGoogle Scholar
  31. Turnbull J (1996) Temporal arteritis and polymyalgia rheumatica: nosographic and nosologic considerations. Neurology 46:901–906CrossRefPubMedGoogle Scholar
  32. Weyand CM, Goronzy JJ (1999) Arterial wall injury in giant cell arteritis. Arthritis Rheum 42:844–885CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Deutsche Gesellschaft für NeurologieDGNBerlinDeutschland

Personalised recommendations